awmsg logo

human normal immunoglobulin (Aragam®)

Reference No. 1548

Publication date:

Appraisal information

human normal immunoglobulin (Aragam®) 50 mg/ml solution for infusion

Company: Oxbridge Pharma Ltd
BNF category: Immunological products and vaccines
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 08/03/2012

Current Progress

Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, human normal immunoglobulin (Aragam®) cannot be endorsed for use within NHS Wales for replacement therapy in primary immunodeficiency syndromes such as: congenital agammaglobulinemia and hypogammaglobulinemia; common variable immunodeficiency; severe combined immunodeficiency and Wiskott Aldrich syndrome; myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinemia and recurrent infections; children with congenital AIDS and recurrent infections; immunomodulation; idiopathic thrombocytopenic purpura; children or adults at high risk of bleeding or prior to surgery to correct the platelet count; Guillain Barré syndrome; Kawasaki disease; allogeneic bone marrow transplantation.
Statement of Advice (SOA)